Cumberland Pharma's Q3 Loss Widens, 9-Month Revenue Up 12.4%

TL;DR

**CPIX is bleeding cash and struggling with product availability, making it a risky bet despite some revenue growth.**

AI Summary

Cumberland Pharmaceuticals Inc. reported a net loss of $1,940,764 for the three months ended September 30, 2025, an increase from a net loss of $1,544,081 in the same period of 2024. For the nine months ended September 30, 2025, the net loss significantly decreased to $1,424,436 from $4,575,956 in the prior year, primarily due to increased net revenues. Total net revenues for the nine-month period rose to $30,842,780 in 2025 from $27,432,376 in 2024, a 12.4% increase. Key product revenue changes include Kristalose decreasing to $7,419,832 from $10,935,702, while Sancuso increased to $8,616,353 from $6,624,102, and Vibativ grew to $6,678,374 from $5,087,983. The company discontinued sales of Omeclamox-Pak due to a lack of commercial inventory and is transitioning to a new manufacturing partner for Vaprisol following an FDA Form 483. Cash and cash equivalents decreased to $15,196,745 as of September 30, 2025, from $17,964,184 at December 31, 2024, partly due to $6,063,778 net cash used in financing activities.

Why It Matters

For investors, the widening Q3 net loss to $1.94 million, despite a 12.4% increase in nine-month net revenues, signals ongoing profitability challenges. The discontinuation of Omeclamox-Pak and manufacturing issues with Vaprisol highlight operational risks and potential revenue instability, impacting future growth prospects. Competitively, the company's reliance on a portfolio of seven FDA-approved products and international partnerships suggests a strategy to diversify, but execution is critical. Employees and customers may face uncertainty if product availability issues persist, potentially affecting market share and brand reputation.

Risk Assessment

Risk Level: high — The company reported a net loss of $1,940,764 for the three months ended September 30, 2025, and cash and cash equivalents decreased by $2,767,439 during the nine-month period. Operational risks are evident with the discontinuation of Omeclamox-Pak due to lack of inventory and ongoing manufacturing transition issues for Vaprisol, which received an FDA Form 483 in Q2 2022.

Analyst Insight

Investors should exercise extreme caution and consider avoiding CPIX until there's clear evidence of sustained profitability and resolution of manufacturing and inventory issues. Monitor future filings for improvements in net income and cash flow from operations, as well as updates on product pipeline and manufacturing stability.

Financial Highlights

debt To Equity

1.55

revenue

$30,842,780

operating Margin

-4.6%

total Assets

$65,898,560

total Debt

$40,097,856

net Income

-$1,424,436

eps

N/A

gross Margin

N/A

cash Position

$15,196,745

revenue Growth

+12.4%

Revenue Breakdown

Key Numbers

• $1,940,764 — Net loss for Q3 2025 (Increased from $1,544,081 in Q3 2024)
• $1,424,436 — Net loss for nine months ended Sept 30, 2025 (Decreased from $4,575,956 in the prior year)
• $30,842,780 — Total net revenues for nine months ended Sept 30, 2025 (Increased 12.4% from $27,432,376 in 2024)
• $15,196,745 — Cash and cash equivalents as of Sept 30, 2025 (Decreased from $17,964,184 at Dec 31, 2024)
• $6,063,778 — Net cash used in financing activities for nine months ended Sept 30, 2025 (Significant cash outflow)
• 14,956,627 — Shares of common stock outstanding as of Nov 5, 2025 (Increased from 13,952,624 shares at Dec 31, 2024)
• $7,419,832 — Kristalose revenue for nine months ended Sept 30, 2025 (Decreased from $10,935,702 in 2024)
• $8,616,353 — Sancuso revenue for nine months ended Sept 30, 2025 (Increased from $6,624,102 in 2024)
• $6,678,374 — Vibativ revenue for nine months ended Sept 30, 2025 (Increased from $5,087,983 in 2024)
• $4,929,498 — Net cash provided by operating activities for nine months ended Sept 30, 2025 (Improved from net cash used of $2,516,804 in 2024)

Key Players & Entities

• Cumberland Pharmaceuticals Inc. (company) — registrant
• FDA (regulator) — U.S. Food and Drug Administration
• Kristalose (company) — product revenue
• Sancuso (company) — product revenue
• Vibativ (company) — product revenue
• Omeclamox-Pak (company) — discontinued product
• Vaprisol (company) — product with manufacturing issues
• FASB (regulator) — Financial Accounting Standards Board
• SEC (regulator) — Securities and Exchange Commission
• Nasdaq Global Select Market (company) — exchange where common stock is registered

FAQ

Risk Factors

• Manufacturing and Supply Chain Disruptions [high — operational]: The company is transitioning to a new manufacturing partner for Vaprisol following an FDA Form 483, indicating potential production delays or quality control issues. Discontinuation of Omeclamox-Pak sales due to inventory shortages highlights ongoing supply chain vulnerabilities.
• FDA Scrutiny and Compliance [medium — regulatory]: An FDA Form 483 for Vaprisol suggests potential compliance issues that could lead to further regulatory action, impacting product availability and market access. Continued adherence to FDA regulations is critical for all product lines.
• Declining Cash Reserves and Increased Losses [medium — financial]: Cash and cash equivalents decreased by $2.77 million to $15.2 million as of September 30, 2025, partly due to $6.06 million in net cash used in financing activities. The company reported a net loss of $1.94 million for Q3 2025, an increase from $1.54 million in the prior year, indicating ongoing financial pressure.
• Product Revenue Volatility [medium — market]: Significant revenue declines in key products like Kristalose (-32.2%) contrast with strong growth in Sancuso (+30.1%) and Vibativ (+31.3%). This revenue volatility requires careful management and strategic focus on high-performing products.

Industry Context

Cumberland Pharmaceuticals operates in the highly competitive pharmaceutical market, focusing on niche therapeutic areas. The industry is characterized by significant R&D investment, stringent regulatory oversight from bodies like the FDA, and reliance on product lifecycle management. Success hinges on effective commercialization of existing products and development of new ones, while managing manufacturing and supply chain complexities.

Regulatory Implications

The FDA Form 483 issued for Vaprisol manufacturing highlights ongoing regulatory scrutiny. This could lead to production disruptions, increased compliance costs, or delays in product availability, impacting revenue streams and investor confidence. Continued vigilance and proactive remediation are crucial.

What Investors Should Do

1. Monitor Vaprisol manufacturing transition and FDA compliance closely.
2. Analyze the sustainability of Sancuso and Vibativ revenue growth.
3. Evaluate the company's cash burn rate and financing activities.
4. Assess the impact of discontinued products on future revenue projections.

Key Dates

• 2025-09-30: End of Third Quarter 2025 — Reporting period for the latest 10-Q, showing increased net loss for the quarter but improved year-to-date net loss due to revenue growth.
• 2025-12-31: End of Fiscal Year 2024 — Prior period balance sheet data for comparison, showing higher cash reserves and a revolving line of credit balance.
• 2024-09-30: End of Third Quarter 2024 — Prior year comparable period for Q3 results, showing a smaller net loss for the quarter.

Glossary

FDA Form 483

A list of observations issued by the U.S. Food and Drug Administration (FDA) that identifies objectionable conditions or practices in any FDA-regulated facility. (Indicates potential compliance issues with Vaprisol manufacturing, leading to supply chain adjustments.)

Accumulated deficit

The cumulative net losses of a company that have not been offset by net income or other gains. (Shows the company has historically incurred more expenses than revenues, with a deficit of $25,392,367 as of September 30, 2025.)

Noncontrolling interests

The portion of equity of a subsidiary that is not attributable to the parent company. (Represents a small portion of the company's equity, with a negative balance of $319,150 as of September 30, 2025.)

Operating lease right-of-use assets

An asset representing the right to use an underlying leased asset for the lease term. (These assets have increased from $6.18 million to $7.57 million, indicating expansion in leased facilities or equipment.)

Year-Over-Year Comparison

Cumberland Pharmaceuticals Inc. reported a 12.4% increase in total net revenues for the nine months ended September 30, 2025, reaching $30.8 million, primarily driven by strong performance in Sancuso and Vibativ. However, this revenue growth was accompanied by a significant decline in Kristalose revenue. While the year-to-date net loss improved substantially from $4.58 million to $1.42 million, the net loss for the third quarter of 2025 increased to $1.94 million from $1.54 million in the prior year. Cash and cash equivalents have decreased, and the company faces operational risks related to manufacturing transitions and regulatory compliance.

Filing Documents

• cpix-20250930.htm (10-Q) — 917KB
• a2025q3-exhibit311.htm (EX-31.1) — 12KB
• a2025q3-exhibit312.htm (EX-31.2) — 12KB
• a2025q3-exhibit321.htm (EX-32.1) — 7KB
• 0001087294-25-000020.txt ( ) — 4623KB
• cpix-20250930.xsd (EX-101.SCH) — 32KB
• cpix-20250930_cal.xml (EX-101.CAL) — 53KB
• cpix-20250930_def.xml (EX-101.DEF) — 127KB
• cpix-20250930_lab.xml (EX-101.LAB) — 448KB
• cpix-20250930_pre.xml (EX-101.PRE) — 305KB
• cpix-20250930_htm.xml (XML) — 475KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 1

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations 2 Condensed Consolidated Statements of Cash Flows 3 Condensed Consolidated Statements of Equity 4 Notes to the Condensed Consolidated Financial Statements 5

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 19

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 33

Controls and Procedures

Item 4. Controls and Procedures 33

– OTHER INFORMATION

PART II – OTHER INFORMATION 34

Legal Proceedings

Item 1. Legal Proceedings 34

Risk Factors

Item 1A. Risk Factors 34

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 34

Other Information

Item 5. Other Information 34

Exhibits

Item 6. Exhibits 35

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (Unaudited) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 15,196,745 $ 17,964,184 Accounts receivable, net 10,430,602 11,701,466 Inventories, net 2,934,723 3,999,995 Prepaid and other current assets 1,377,378 2,786,513 Total current assets 29,939,448 36,452,158 Non-current inventories 9,183,862 11,005,499 Property and equipment, net 293,375 277,365 Intangible assets, net 15,010,795 17,973,449 Goodwill 914,000 914,000 Operating lease right-of-use assets 7,570,452 6,176,923 Other assets 2,986,628 2,784,016 Total assets $ 65,898,560 $ 75,583,410 LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 13,832,497 $ 13,914,266 Operating lease current liabilities 401,445 356,508 Current portion of revolving line of credit — 5,100,000 Other current liabilities 10,076,027 12,250,955 Total current liabilities 24,309,969 31,621,729 Revolving line of credit - long term 5,240,733 10,176,170 Operating lease non-current liabilities 4,595,768 4,939,739 Other long-term liabilities 5,951,386 6,299,795 Total liabilities 40,097,856 53,037,433 Equity: Shareholders' equity: Common stock— no par value; 100,000,000 shares authorized; 14,956,627 and 13,952,624 shares issued and outstanding as of September 30, 2025, and December 31, 2024, respectively 51,512,221 46,821,425 Accumulated deficit ( 25,392,367 ) ( 23,967,931 ) Total shareholders' equity 26,119,854 22,853,494 Noncontrolling interests ( 319,150 ) ( 307,517 ) Total equity 25,800,704 22,545,977 Total liabilities and equity $ 65,898,560 $ 75,583,410 See accompanying Notes to Condensed Consolidated Financial Statements. 1 CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES Condensed Consolidated Statements of Operations (Unaudited) Three months ended September 30, Nine months ended September 30, 2025 2024 2025 2024

View Full Filing

View this 10-Q filing on SEC EDGAR